9th Annual Biomarkers Congress

Schedule of Presentations:

Friday, October 5, 2007
07:00:00 Registration and Continental Breakfast
07:25:00 Welcome and Introductions
07:30:00 Keynote 1: new guidelines for response and risk stratification in lymphomas
08:00:00 Clinical Challenges in Low-Grade Lymphoma
08:20:00 Clinical Challenges in Diffuse Large B-Cell Lymphoma
08:40:00 Clinical Challenges in Mantle Cell Lymphoma
09:00:00 Clinical Challenges in Cutaneous T-Cell Lymphomas
09:20:00 Panel Discussion
09:40:00 Break
09:55:00 Pro Case-Based Debate # 1: Should All Patients With Indolent Lymphoma Receive Maintenance Therapy?
10:15:00 Con Case-Based Debate # 1: Should All Patients With Indolent Lymphoma Receive Maintenance Therapy?
10:35:00 Controversy # 1: XRT in Hodgkin Lymphoma
10:55:00 Controversy # 2: PET in Lymphomas
11:15:00 Case-Based Debate # 2: Does RIT Have a Place in Lymphomas in 2007? Pro
11:35:00 Case-Based Debate # 2: Does RIT Have a Place in Lymphomas in 2007? Con
11:55:00 Panel Discussion
12:15:00 Lunch Break
13:15:00 Clinical Challenges in AML
13:35:00 Clinical Challenges in Newly Diagnosed CML
13:55:00 Clinical Challenges in CML Resistant to TKIs
14:15:00 Clinical Challenges in MDS
14:35:00 Molecular Tests in Myeloid Malignancies: When, Who, How
14:55:00 Panel Discussion
15:15:00 Break
15:30:00 Keynote # 2: Biology of JAK2 CMD
16:00:00 Keynote # 3: Clinical Challenges in JAK2 CMD
16:30:00 Adjourn
Saturday, October 6, 2007
07:00:00 Continental Breakfast
07:30:00 Keynote 4: a magic bullet for PNH
08:00:00 Clinical Challenges in Younger Patients With MM
08:20:00 Clinical Challenges in Older Patients With MM
09:00:00 Case-Based Debate # 3: Should All Patients with MM Receive Maintenance Therapy? Pro
09:20:00 Case-Based Debate # 3: Should All Patients with MM Receive Maintenance Therapy? CON
09:40:00 Panel Discussion
10:00:00 Break
10:15:00 Controversy # 3: Risk Stratification in MM
10:35:00 Controversy # 4: Waldenström Macroglobulinemia: Is There a Standard of Care?
10:40:00 Clinical Challenges in Refractory Patients With MM
10:55:00 Controversy # 5: Appropriate Management of Bone
11:15:00 Controversy # 6: Smoldering Myeloma: To Treat, or Not to Treat?
11:35:00 Controversy # 7: Response Assessment and Treatment of AL Amyloidosis
11:55:00 Panel Discussion
12:55:00 Break to Lunch
13:15:00 Controversy # 8: Role of SCT in CML
13:35:00 Controversy # 9: Role of SCT in CLL and Lymphoma
13:55:00 Controversy # 10: Role of SCT in Myeloma
14:15:00 Case-Based Debate # 4: Will RIC Be Obsolete in 2008
14:35:00 PRO
14:55:00 CON
15:15:00 Panel Discussion
15:35:00 Break
15:50:00 Third-Generation Anti-CD20 Antibodies in Lymphoma
16:10:00 JAK2 Inhibitors in CMD
16:30:00 Flavopiridol in CLL
16:50:00 Emerging Proteasome Inhibitors in Myeloma
17:10:00 Question-and-Answer Session
17:30:00 Adjourn
Sunday, October 7, 2007
07:30:00 Registration and Continental Breakfast
08:00:00 Keynote 5: Changing Paradigms in the Use of EPO in Cancer Medicine
08:30:00 Management of Iron Overload
08:50:00 Optimizing the Use of Myeloid Growth Factors in 2007
09:10:00 Use of Prophylactic Anti-Infective Agents in the Nontransplantation Setting
09:30:00 Panel Discussion
09:50:00 Break
10:05:00 How Many Faces Does CLL Have?
10:25:00 Clinical Challenges in Younger Patients With CLL
10:45:00 Clinical Challenges in Older Patients With CLL
11:05:00 Pro
11:25:00 Con
11:45:00 Panel Discussion
12:05:00 Concluding Remarks and Adjourn
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.